Sign In
Buy LGVN
$0.80
-0.0197 (-2.40%)
At Close: Jun 22, 2026
Why Is Longeveron (LGVN) Stock Up 82% Today?
07:56am, Monday, 08'th Apr 2024
Longeveron (NASDAQ: LGVN ) stock is rocketing higher on Monday after the clinical-stage biotechnology company revealed plans for a proposed public share offering. Longeveron intends to offer up 2,46
Longeveron Announces 1-for-10 Reverse Stock Split
04:01pm, Tuesday, 19'th Mar 2024
MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical
Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript
09:56pm, Tuesday, 27'th Feb 2024
Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript
Longeveron Reports Year-End 2023 Results and Provides Corporate Update
04:05pm, Tuesday, 27'th Feb 2024
Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024
04:05pm, Wednesday, 21'st Feb 2024
MIAMI, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, a
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™
08:00am, Monday, 29'th Jan 2024
U.S. patent allowance impacts Aging-related Frailty patients receiving vaccines and builds upon a growing patent estate protecting the use of Lomecel-B™ U.S. patent allowance impacts Aging-related F
Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
04:05pm, Friday, 22'nd Dec 2023
MIAMI, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening a
Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023
08:00am, Friday, 03'rd Nov 2023
MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chron
Longeveron stock jumps on Alzheimer's trial results
08:13am, Thursday, 05'th Oct 2023
Longeveron Inc. shares LGVN, +4.58% jumped 16% premarket on Thursday after the clinical-stage biotech company announced positive results from a trial of its Alzheimer's treatment Lomecel-B.
Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference
08:00am, Tuesday, 05'th Sep 2023
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for lif
Longeveron Inc. (LGVN) Q2 2023 Earnings Call Transcript
10:16pm, Friday, 11'th Aug 2023
Longeveron Inc. (NASDAQ:LGVN ) Q2 2023 Earnings Conference Call August 11, 2023 8:00 AM ET Company Participants Mike Moyer - Managing Director, LifeSci Advisors, LLC Wa'el Hashad - Chief Executive Off
Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023
08:00am, Monday, 07'th Aug 2023
MIAMI, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chron
Longeveron Inc. (LGVN) Q1 2023 Earnings Call Transcript
02:14pm, Friday, 12'th May 2023
Longeveron Inc. (NASDAQ:LGVN ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants James Clavijo - Chief Financial Officer Wa'el Hashad - Chief Executive Officer Chris Min -
LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates
08:32am, Friday, 12'th May 2023
Longeveron (NASDAQ: LGVN ) just reported results for the first quarter of 2023. Longeveron reported a loss per share of 22 cents.
Why Is Longeveron (LGVN) Stock Up 30% Today?
10:42am, Tuesday, 09'th May 2023
Longeveron (NASDAQ: LGVN ) stock is on the move Tuesday after releasing long-term survival data from its HLHS treatment. According to the company, all 10 patients that received Lomecel-B during their
